Ipponi Alessandra, Moriconi Sabina, Pelagotti Filippo, Lombardo Giuseppe, Pagni Marco, Colombai Renato, Donati Maria Grazia, Banfi Roberto, Roccato Enrico
Dipartimento del Farmaco, Azienda USL11, Empoli, Firenze.
Recenti Prog Med. 2008 Sep;99(9):443-50.
Dispensing medication at the discharge of patients is an activity that allows to the Pharmacy Department to have a privileged point of view about prescribing new drugs and therapies. During last year we met several prescriptions for new drugs utilized in the treatment of pulmonary arterial hypertension (PAH), These prescriptions are the mirror of the avalaibility of new specific drugs. PAH is a rare and fatal disease; current disease-specific therapeutic interventions in PAH established pathways in disease treatment: prostacyclin, endothelin receptors antagonist. Several studies indicate that sildenafil, an oral phosphodiesterase type-5 inhibitor, may also offer benefits in the pharmacological management of PAH as well as tadalafil or vardenafil too. We collected data from our Pharmacy patient's database to evaluate the impact of this rare disease on our setting, to analyse the patterns of prescription of our physicians and to think specific health policy or pathways for the patients suffering from this disease.
在患者出院时调配药物是一项让药剂科能够对新药和新疗法的处方情况有独到见解的活动。在过去一年里，我们遇到了几例用于治疗肺动脉高压（PAH）的新药处方，这些处方反映了新型特效药物的可获得性。PAH是一种罕见的致命疾病；目前PAH的疾病特异性治疗干预措施确立了疾病治疗的途径：前列环素、内皮素受体拮抗剂。多项研究表明，口服5型磷酸二酯酶抑制剂西地那非在PAH的药物治疗中可能也有益处，他达拉非和伐地那非也是如此。我们从药房患者数据库中收集数据，以评估这种罕见疾病对我们医院环境的影响，分析我们医生的处方模式，并为患有这种疾病的患者思考具体的卫生政策或治疗途径。
